Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

PBI-410 · BHV-1510, GQ1010

Antibody-drug conjugate · Cytotoxic, directed at TROP-2 (TACSTD2) · developed by Biohaven

Phase 1/2 Most advanced trial

BHVN Developer

1 Registered trials

What is PBI-410?

PBI-410 is an antibody-drug conjugate targeting TROP-2, a tumor-associated antigen overexpressed in various solid tumors. The anti-TROP-2 antibody delivers a camptothecin analog that inhibits DNA topoisomerase-1, leading to DNA replication inhibition, cell cycle arrest, and tumor cell apoptosis. It is studied in solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: BHV-1510, GQ1010
Drug type: Antibody-drug conjugate
Targets: TROP-2 (TACSTD2)
Mechanism: Cytotoxic, directed at TROP-2 (TACSTD2)
Pathways: DNA topoisomerase-1 inhibition, DNA replication inhibition, cell cycle arrest, apoptosis
Therapy area: Oncology
Developer: Biohaven (BHVN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06384807	Phase 1/2	Solid Tumor	Recruiting	BHVN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Solid Tumor

Other drugs acting on TACSTD2

Datopotamab Deruxtecan FDA approved Sacituzumab Govitecan FDA approved Sacituzumab Tirumotecan Phase 3

More from Biohaven

BHV-1300 Phase 3 BHV-1400 Phase 3 BHV-1530 Phase 1 BHV-2100 Phase 2 BHV-700 Phase 1 BHV-7000 Phase 2/3 BHV-8000 Phase 2/3 Talditercept Alfa Phase 3 Troriluzole Phase 3 Verdiperstat Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHVN page.

Follow BHVN, the company behind PBI-410

See BHVN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHVN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z